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Abstract
Background: Due to the global occurrence of multi-drug-resistant malarial parasites (Plasmodium falciparum), the anti-malarial
drug most effective against malaria is artemisinin, a natural product (sesquiterpene lactone endoperoxide) extracted from sweet
wormwood (Artemisia annua). However, artemisinin is in short supply and unaffordable to most malaria patients. Artemisinin
can be semi-synthesized from its precursor artemisinic acid, which can be synthesized from simple sugars using microorganisms
genetically engineered with genes from A. annua. In order to develop an industrially competent yeast strain, detailed analyses of
microbial physiology and development of gene expression strategies are required.
Results: Three plant genes coding for amorphadiene synthase, amorphadiene oxidase (AMO or CYP71AV1), and cytochrome
P450 reductase, which in concert divert carbon flux from farnesyl diphosphate to artemisinic acid, were expressed from a single
plasmid. The artemisinic acid production in the engineered yeast reached 250 μg mL-1 in shake-flask cultures and 1 g L-1 in bio-
reactors with the use of Leu2d selection marker and appropriate medium formulation. When plasmid stability was measured,
the yeast strain synthesizing amorphadiene alone maintained the plasmid in 84% of the cells, whereas the yeast strain synthesizing
artemisinic acid showed poor plasmid stability. Inactivation of AMO by a point-mutation restored the high plasmid stability,
indicating that the low plasmid stability is not caused by production of the AMO protein but by artemisinic acid synthesis or
accumulation. Semi-quantitative reverse-transcriptase (RT)-PCR and quantitative real time-PCR consistently showed that
pleiotropic drug resistance (PDR) genes, belonging to the family of ATP-Binding Cassette (ABC) transporter, were massively
induced in the yeast strain producing artemisinic acid, relative to the yeast strain producing the hydrocarbon amorphadiene
alone. Global transcriptional analysis by yeast microarray further demonstrated that the induction of drug-resistant genes such
as ABC transporters and major facilitator superfamily (MSF) genes is the primary cellular stress-response; in addition, oxidative
and osmotic stress responses were observed in the engineered yeast.
Conclusion: The data presented here suggest that the engineered yeast producing artemisinic acid suffers oxidative and drug-
associated stresses. The use of plant-derived transporters and optimizing AMO activity may improve the yield of artemisinic acid
production in the engineered yeast.
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Background
Terpenoids (or isoprenoids) are a large and diverse class
of natural products derived from five-carbon building
unit, isopentenyl diphosphate (IPP) [1,2]. The central pre-
cursor IPP and its isomer (dimethyl allyl diphosphate,
DMAPP) are converted to the 10-carbon geranyl diphos-
phate (GPP), the 15-carbon farnesyl diphosphate (FPP),
and the 20-carbon geranylgeranyl diphosphate (GGPP)
by the condensation reactions of GPP, FPP, and GGPP
synthase, respectively. At the entry-point of terpenoid bio-
synthesis, the IPP and its derivatives (i.e., GPP, FPP, and
GGPP) are transformed to hundreds of unique hydrocar-
bon olefins by terpene synthases via carbocation interme-
diates [3]. These terpene backbones are then decorated by
modifying enzymes such as cytochrome P450 monooxy-
genase (P450), oxidoreductase, and other transferase
enzymes that provide various functional moieties (e.g.,
methyl, acetyl, phenolic groups).
In primary metabolism, terpenoids are indispensable
components for various physiological processes, such as
respiration (ubiquinone), photosynthesis (plastoqui-
none), membrane fluidity (cholesterol), and intracellular
signaling cascades (protein prenylation). Terpenoid
metabolism is also responsible for creating a wide array of
related, yet chemically distinct natural products, which
play important roles in interactions among organisms and
defense mechanisms against biotic stresses [4,5]. Many of
these terpenoid natural products have found use as phar-
maceuticals (e.g., taxol as an anti-cancer drug), nutraceu-
ticals (e.g., lycopene as an anti-oxidant), aromas and
flavors (e.g., nootkatone as an aroma), and industrial
chemicals (e.g., natural rubber). The transformation of
IPP and its related derivatives to highly complex terpe-
noids has been an area of active biochemical and bio-
engineering studies [6].
The pharmaceutical, chemical, and food industries that
supply terpenoid commodities face two critical issues.
First, the chemical complexities of terpenoids hinder eco-
nomic chemical synthesis of terpenoids. To date, the sup-
ply of many terpenoid compounds still depends on the
isolation of natural terpenoids or the pathway intermedi-
ates from plant sources. Second, chemical intermediates
and solvents required for the organic chemical synthesis
of terpenoids are often petroleum-derived chemicals
whose availability is finite. To circumvent these problems,
current biotechnological efforts have been focused on
devising novel biological processes to manufacture com-
plex terpenoids using enzymes and engineered microbial
platforms. One example of biological manufacturing of
terpenoids is the production of the anti-malarial drug
artemisinin precursor, artemisinic acid, using recom-
binant enzymes in microbial platforms [7,8].
Artemisinin is a sesquiterpene lactone endoperoxide
extracted from the medicinal plant, sweet wormwood
(Artemisia annua). Artemisinin is a potent anti-malarial
drug whose mode of action in curing malaria is proposed
to include inhibition of the SERCA (Sarco/Endoplasmic
Reticulum Ca2+-ATPase) activity of Plasmodium falciparum
[9]. Artemisinin Combination Therapy (ACT) has been
recommended as the first-line medication to patients liv-
ing in areas where multi-drug resistant strains of Plasmo-
dium spp. are endemic [10,11]. However, the lack of
sufficient raw material, artemisinin, and the cost associ-
ated with the drug's manufacture have limited the supply
of ACT to malaria sufferers in the Developing World [12].
At this moment, scientific effort is being directed to
develop a biological method to supply sufficient and reli-
able quantities of artemisinic acid, a direct precursor of
artemisinin. The introduction and optimization of the
mevalonate pathway in E. coli increased production of
FPP to 0.5 gram L-1 as measured by amorphadiene pro-
duction [13]. Similar flux-enhancement in S. cerevisiae
increased amorphadiene production to 150 mg L-1 [7,14].
Expression of amorphadiene synthase (ADS), amorphadi-
ene C12 oxidase (AMO or CYP71AV1), and its redox part-
ner cytochrome P450 reductase (CPR) in the flux-
enhanced E. coli or S. cerevisiae demonstrated that more
than 100 mg artemisinic acid L-1 culture can be produced
in both platforms at a laboratory scale [7,8]. The efficient
conversion of amorphadiene to artemisinic acid by S. cer-
evisiae expressing the ER-bound AMO demonstrated it to
be an ideal microbial platform to functionally express
genes encoding membrane-bound enzymes.
Following up from the report of artemisinic acid manufac-
ture in the engineered yeast [7], we evaluated and further
improved the engineered yeast as a microbial host to pro-
duce the drug precursor artemisinic acid. We show here
that the production of artemisinic acid can be increased
by employing a high-copy plasmid system. We further
assessed the response of the engineered yeast to artem-
isinic acid synthesis and accumulation by analyzing the
global transcript profile and by conducting targeted gene
expression analysis of multi-drug resistant genes. The data
demonstrates the potential use of the engineered yeast to
produce drug precursors and also suggests molecular strat-
egies to be employed to further improve the artemisinic
acid production levels.
Results
Low plasmid stability in yeast strain engineered to produce 
artemisinic acid
Artemisinic acid is a key precursor for the anti-malarial
drug, artemisinin. We have previously reported an engi-
neered yeast strain harboring two plasmids that can syn-
thesize ~100 mg artemisinic acid L-1 culture in a bioreactor
[7]. In the previous study, expression of the three plantBMC Biotechnology 2008, 8:83 http://www.biomedcentral.com/1472-6750/8/83
Page 3 of 14
(page number not for citation purposes)
genes was achieved using the pRS425-Leu  plasmid for
amorphadiene synthase (ADS) expression and using the
pESC-Ura plasmid for amorphadiene oxidase (AMO) and
cytochrome P450 reductase (CPR) expressions. The plas-
mid stability of the engineered yeast was evaluated after
culturing the yeast strain in galactose selective medium.
After culturing for 120 hr, only 28 ± 10% (mean ± SD, n =
3) of the engineered yeast contained both pRS425-
Leu::ADS and pESC-Ura::AMO/CPR plasmids, indicating
that 72% of the yeast cells lost the leucine, uracil, or both
selectable markers. This result led us to systematically
examine the plasmid stability of engineered yeast strains
with the aim of devising methods to increase the yield of
artemisinic acid production. We analyzed the production
of amorphadiene and artemisinic acid separately by con-
structing a single vector encoding either ADS  or  ADS/
AMO/CPR (Figure 1A and Figure 2A).
Improved production of amorphadiene in engineered yeast
The Leu2d allele contains a deleted promoter, leaving only
29-bp of the Leu2 promoter region in the Leu2 expression
cassette. To compensate for the weakened Leu2 expres-
sion, S. cerevisiae selects for significantly higher plasmid
copy number [15]. The ADS  gene was expressed in
pRS425-Leu2  (EYP224) or in the newly constructed
pRS425-Leu2d  plasmid backbone (EPY230, Figure 1A)
using selective (CSM) or non-selective medium (YPG). As
amorphadiene is volatile, it was collected by overlaying
dodecane in the yeast culture.
Amorphadiene dissolved in the dodecane layer was quan-
tified by gas-chromatography. In the selective medium,
changing expression of ADS from pRS425-Leu2 to pRS425-
Leu2d increased amorphadiene production 1.3 fold (from
90 ± 3 μg mL-1 to 120 ± 4 μg mL-1), whereas changing the
culture medium from selective to non-selective rich
medium using the Leu2 plasmid (pRS425-Leu2) increased
amorphadiene production 5.9 fold (Figure 1B). Expres-
sion of ADS from pRS425-Leu2d in non-selective medium
increased amorphadiene production by 8.6-fold (781 ±
34 μg mL-1 culture). Specific amorphadiene production
(i.e., amorphadiene production per OD unit in a given
time) closely followed the time-course production pattern
for total amorphadiene, although the production differ-
ence in non-selective medium was marginal (Figure 1C).
The stability of pRS425-Leu2::ADS plasmid in either selec-
tive or non-selective medium was not significantly differ-
ent, exhibiting more than 50% plasmid stability at 144-hr
post-induction in all conditions (Figure 1D). Interest-
ingly, the stability of pRS425-Leu2d::ADS in non-selective
medium was very high (84% ± 4) even at 144-hr post-
induction. The high stability of pRS425-Leu2d::ADS
implies that the Leu2d selectable marker enables yeast to
maintain high plasmid stability in non-selective medium.
Improved production of artemisinic acid in engineered 
yeast
Plasmids containing three plant genes (ADS, AMO, CPR)
for artemisinic acid biosynthesis were constructed in
pESC-Leu2 or pESC-Leu2d (Figure 2A). These two plasmids
are referred to as pESC-Leu2-T  (triple genes) or pESC-
Leu2d-T. Prior to testing the artemisinic acid production
by these two plasmids, the expression of ADS  in the
pRS425-Leu2d and pESC-Leu2d backbones was compared
to ensure that ADS is expressed similarly in the two differ-
ent plasmid backbones. The engineered yeast strain har-
boring either pRS425-Leu2d::ADS (EPY230; see Table 1) or
pESC-Leu2d::ADS  (EPY306) routinely produced 800 μg
amorphadiene mL-1 culture. There was no difference in
their plasmid stabilities (85% ± 3 for pRS425-Leu2d::ADS
and 90% ± 10 for pESC-Leu2d::ADS; n = 3). Thus, ADS
expression was not affected by the type of plasmid back-
bones used.
To evaluate artemisinic acid production, the EPY300
strain was transformed either with pESC-Leu2-T (creating
strain EPY305) or pESC-Leu2d-T (creating strain EPY307).
EPY305 produced 31 ± 3 mg L-1 (n = 3) artemisinic acid,
which is comparable to the level of artemisinic acid pro-
duced by the strain harboring the two-plasmid system [7].
Changing the selection marker from Leu2  to  Leu2d
increased artemisinic acid production by 1.9-fold in selec-
tive medium, whereas changing the medium from selec-
tive to non-selective using the Leu2  plasmid increased
artemisinic acid production by 4.1-fold (Figure 2B). The
combination of the Leu2d selection marker and non-selec-
tive, rich medium increased the production of artemisinic
acid by 8.1 fold. As a result, the final titer reached 254 ±
48 mg L-1culture (Figure 2B). The production yield of
amorphadiene and artemisinic acid (Figure 1B and 2B)
indicates that 32% of the amorphadiene was oxidized by
AMO and CPR in the engineered yeast.
The time course data of specific artemisinic acid produc-
tion of the triple gene-expressing yeasts were clearly differ-
ent from those of amorphadiene production of the ADS-
expressing yeasts (Figure 2C). The yeast strain expressing
the three genes from pESC-Leu2 (EPY305) in non-selective
medium showed greatly decreased specific productivity
(~10 μg OD-1 mL-1). Thus, without selection, the three
plant genes need to be expressed from the high-copy
pESC-Leu2d plasmid in order to maintain high specific
productivity.
Plasmid stabilities of the triple-gene expression vectors
were significantly different from those of ADS-expressing
plasmids (Figure 2D). Plasmid stability of pESC-Leu2-T in
selective medium (50 ± 15%) was 2.8-fold higher than
that in non-selective medium (18 ± 3%) at 120-hr post-
induction. Similarly, the plasmid stability of pESC-Leu2d-BMC Biotechnology 2008, 8:83 http://www.biomedcentral.com/1472-6750/8/83
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T in selective medium (77 ± 3%) was 1.9-fold higher than
that in non-selective medium (40 ± 14%). These results
showed that engineered yeasts lose the plasmids coding
for the three plant genes when grown in non-selective rich
medium and that the Leu2d selection marker is required
for yeast to retain plasmids. The low plasmid stability for
yeast expressing the three plant genes from pESC-Leu2 in
non-selective medium is consistent with the significantly
decreased specific productivity of the same strain (Figure
2C).
In order to evaluate the potential use of the yeast strain for
industrial fermentation purposes, the two auxotropic
markers (lys2Δ0 ura3Δ0) were repaired, and the resulting
Amorphadiene production in the engineered yeast strain Figure 1
Amorphadiene production in the engineered yeast strain. (A) Plasmid harboring ADS under control of the Gal1 pro-
moter used to produce amorphadiene in EPY300. Total (B) and specific (C) amorphadiene production from EPY300 expressing 
ADS on either pRS425-leu2 or pRS425-leu2d cultured in either CSM or YPG medium. Circles and diamonds indicate the leu2d 
and leu2 selection markers, respectively. Unfilled symbols indicate selective, minimal medium (CSM), and filled symbols indicate 
non-selective, rich medium (YPG). (D) Plasmid stabilities of yeast harboring pRS425-leu2::ADS or pRS425-leu2d::ADS grown in 
either CSM or YPG medium at 24, 72, and 144 hr post-induction. Data are mean ± standard deviation from three replicate 
experiments.BMC Biotechnology 2008, 8:83 http://www.biomedcentral.com/1472-6750/8/83
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yeast strain (EPY330) was cultured in a fed-batch culture
in a bio-reactor. Without culture optimization, the yeast
strain produced 1.06 g artemisinic acid L-1 after culturing
for 144 hr (see Materials and Methods for details). These
data strongly suggest the industrial potential of this yeast
strain for artemisinic acid production.
Restoration of high plasmid stability by point-mutation of 
AMO
Apparently, the plasmid stabilities were not affected by
ADS gene expression and amorphadiene production (Fig-
ure 1D). However, a comparison of yeast strains produc-
ing amorphadiene to those producing artemisinic acid
showed that plasmid stabilities were affected by AMO and
CPR expression. To distinguish whether the plasmid loss
was due to the high expression of membrane-bound AMO
or due to the high level of artemisinic acid production, a
point mutation (Cys to Gly at the 439th residue) was
introduced into AMO at the cysteine residue that is con-
served in all P450 enzymes. This AMO knock-out of pESC-
Leu2d-T is referred to as pESC-Leu2d-TKO. GC-MS analysis
confirmed that the engineered yeast strain containing the
Artemisinic acid production by the engineered yeast strain Figure 2
Artemisinic acid production by the engineered yeast strain. (A) Plasmid encoding ADS, AMO, and CPR under control of 
either the Gal1 or Gal10 promoter used to produce artemisinic acid by EPY300. Total (B) and specific (C) artemisinic acid pro-
duction from EPY300 strain expressing ADS, AMO, and CPR from either pESC-leu2 or pESC-leu2d cultured in either CSM or 
YPG medium. T indicates triple genes (ADS, AMO, and CPR). Circles and diamonds indicate leu2d and leu2 selection markers. 
Unfilled symbols indicate selective, minimal medium (CSM), and filled symbols indicate non-selective, rich medium (YPG). (D) 
Plasmid stabilities of yeast harboring either pRS425-leu2::ADS/AMO/CPR or pRS425-leu2d::ADS/AMO/CPR grown in either CSM 
or YPG medium at 24, 72, and 120-hr post-induction.BMC Biotechnology 2008, 8:83 http://www.biomedcentral.com/1472-6750/8/83
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pESC-Leu2d-TKO (EYP309) did not produce artemisinic
acid but produced a high level of amorphadiene, indicat-
ing that the C439G point mutation completely abolished
the catalytic activity of AMO (data not shown). Produc-
tion of the AMO protein in EPY309 was also verified by
Western-blot using an anti-AMO polyclonal antibody
(data not shown). Together, these data demonstrate that
EPY309 is producing an inactive AMO protein. EPY300
was transformed with either pESC-Leu2d-T (EPY307) or
pESC-Leud2-TKO (EPY309), and the plasmid stabilities of
these two strains were measured after culturing at 96-hr in
non-selective medium. The stability of pESC-Leu2d-T (28
± 20%) was comparable to the previous data, whereas the
stability of pESC-Leu2d-TKO was 74 ± 20% (Figure 3).
This plasmid stability is much closer to that of the plasmid
expressing ADS alone (Figure 1D). Based on these data,
we concluded that artemisinic acid synthesis was the
cause for the low plasmid stability.
Induction of ABC transporter by endogenous production of 
artemisinic acid
The two engineered yeast strains (EPY307 and EPY309)
have a single nucleotide difference in their plasmids,
which results in the different oxidation level of the terpe-
noid product (i.e., amorphadiene versus artemisinic
acid). Considering the neutrality of the cytosol and a pre-
dicted pKa of 4.34 ± 0.11 for artemisinic acid [Scifinder
data; calculated using Advanced Chemistry Development
http://www.acdlabs.com Software V8.14 for Solaris], it is
likely that artemisinic acid is present as an ionized form in
the yeast cytosol, and hence active yeast transporters
might be involved in transporting the polar artemisinic
acid out of the cell to lessen its potential toxicity. To exam-
ine if the cellular stresses caused by a high level of oxi-
dized terpenoids can evoke the induction of genes
involved in pleiotropic drug resistance (PDR), the tran-
scription of five yeast ATP-Binding Cassette (ABC) trans-
porters (PDR5, PDR12, PDR15, YOR1, and SNQ2) and
two known transcription factors (PDR1 and PDR3) for the
PDR response were compared by semi-quantitative
reverse transcriptase (RT)-PCR. A remarkable transcrip-
tional induction of PDR5 was found in the yeast strain
producing artemisinic acid relative to the strain expressing
the inactivated AMO (Figure 4A). Expression of three
other ABC transporters (PDR15, YOR1, and SNQ2) was
also significantly induced in the yeast strain producing
artemisinic acid relative to the yeast strain containing the
inactivated  AMO; induction of PDR12  expression was
insignificant. In addition, up-regulated expression of the
PDR3  transcription factor was noticeable after 24 hrs,
while that of PDR1 was indiscernible.
In order to quantify the magnitude of induction, the tran-
scripts of these genes were analyzed by quantitative real-
time RT-PCR. At 24 hrs post-induction, PDR5  was
induced by 15.6 fold; PDR15,  YOR1  and  SNQ2  were
induced 6 to 9 fold; and PDR3 was induced by 2.4 fold
(Figure 4B). Although expression induction of these genes
was attenuated at 96 hrs, significant expression was still
Table 1: Strain names and genotypes
Strains Genotype Plasmid References
BY4742 MATαα his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0 none 41
EPY224 MATαα his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0 PGAL1-tHMGR PGAL1-upc2-1 erg9::PMET3-ERG9 
PGAL1-tHMGR PGAL1-ERG20
pRS425-Leu::ADS 7
EPY300 MATαα his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0 PGAL1-tHMGR PGAL1-upc2-1 erg9::PMET3-ERG9 
PGAL1-tHMGR PGAL1-ERG20
none 7
EPY230 EPY300 pRS425-Leu2d::ADS This study
EPY305 EPY300 pESC-Leu:: ADS/AMO/CPR This study
EPY306 EPY300 pESC-Leu2d::ADS This study
EPY307 EPY300 pESC-Leu2d:: ADS/AMO/CPR This study
EPY309 EPY300 pESC-Leu2d:: ADS/AMO-KO/CPR This study
EPY330 lys2Δ0 ura3Δ0 repaired EPY300 pESC-Leu2d:: ADS/AMO/CPR This study
EPY338 lys2Δ0 ura3Δ0 repaired EPY300 pESC-Leu2d:: ADS/AMO-KO/CPR This study
Plasmid stabilities of transgenic yeast strains Figure 3
Plasmid stabilities of transgenic yeast strains. EPY307 
harbors pESC-Leu2d-T plasmid and EPY309 harbors pESC-
Leu2d-TKO, which carries AMO inactivated by the C439G 
point mutation.BMC Biotechnology 2008, 8:83 http://www.biomedcentral.com/1472-6750/8/83
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detectable. These data were consistent with and corrobo-
rate those obtained by semi-quantitative RT-PCR. Relative
transcriptional analyses of yeast ABC transporters clearly
demonstrated that one of the primary cellular responses
caused by de novo artemisinic acid synthesis in engineered
yeast is rapid transcriptional activation of various ABC
transporters.
Global transcriptional analysis by microarray
Up-regulation of PDR transporter expression suggests that
in vivo production of artemisinic acid triggers a stress
adaptation response in yeast. In order to further character-
ize the stress responses accompanying AMO activity and
artemisinic acid production, we compared transcript pro-
files of an artemisinic acid-producing strain (EPY330) and
Reverse-transcriptase PCR analysis of selected genes involved in multiple pleiotropic drug resistance Figure 4
Reverse-transcriptase PCR analysis of selected genes involved in multiple pleiotropic drug resistance. (A) Semi-
quantitative RT-PCR conducted with RNA extracted after 24 hr of induction from EPY307 (artemisinic acid producer) and 
EPY309 (amorphadiene producer). Number of PCR Cycles used: ACT1: 23; PDR5, PDR15, SNQ2: 24; YOR1:27; PDR1:28; 
PDR3, PDR12:30. (B) Quantitative real-time RT-PCR conducted with samples harvested at 24 and 96 h post-induction.BMC Biotechnology 2008, 8:83 http://www.biomedcentral.com/1472-6750/8/83
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that of a strain expressing the inactivated AMO (EPY338).
Expression of the triple-gene constructs in five independ-
ent transformants for each strain (active and inactive
AMO) were induced and harvested at 24, 48 and 72 hours
after induction.
A total of 2,156 genes were found to be significantly dif-
ferentially expressed in at least one experimental time
point, of which 488 were up-regulated and 256 were
down-regulated in the producer strain by more than 2-
fold in at least one time point (see additional file 1 for a
complete list of genes; the microarray data set was depos-
ited at the Gene Expression Omnibus database, GEO
Accession Number: GSE11620). Not unexpectedly, sev-
eral known or putative PDR transporters (PDR5, PDR10,
PDR11, PDR12, PDR15, PDR16, PDR17, YOR1 and
SNQ2) were found among the differentially expressed
genes, some of which are among the genes with the
strongest up-regulation observed (Figure 5). These results
are generally very similar to the results obtained by quan-
titative PCR for these genes, although PDR12 was found to
be significantly up-regulated (1.9-fold) by microarrays at
72 h post-induction. Several transporters of the major
facilitator superfamily (MFS) were also strongly up-regu-
lated in the artemisinic acid-producing strain, including
transporters associated with multiple drug resistance
(SGE1, DTR1, YCL073C, TPO1, TPO4) and the hexose
transporters (HXT1, HXT9 and HXT11), which have been
shown to be transcriptionally controlled by PDR tran-
scription factors Pdr1p and Pdr3p [16,17]. This important
and widespread up-regulation of transcription of drug
transporters often persisted at least 72 hr after induction.
A number of genes in the gene ontology categories
"response to drugs" or "response to toxin" (CCR4, RIB1,
PPA1, PRM7, MAC1, YLR056C, AAD6, AAD10, RTA1,
YLR346C, YML131W, GTT2, GRE2) were also strongly up-
regulated.
The T-profiler software [18] and the YEASTRACT data-
base [19] were used to interpret the gene expression pro-
files at the 24-hr time point by finding consensus motifs
upstream of significantly represented groups of genes
and associated transcription factors. Three different
upstream regulatory consensus motifs were predicted to
have a significant impact in the response to artemisinic
acid production: TCCGYGGR, which can be bound by
the drugs and stress -responsive transcription factors
Pdr3p, Pdr8p, Yrr1p and Hsf1p; CCCCT, which can be
bound by the drugs and stress-responsive transcription
factor Msn2p/Msn4p; and YYACCCG, which can be
bound by Reb1p, a general RNA polymerase factor, but
also by Hsf1p, a general stress response-associated tran-
scription factor. Similar results were obtained after 48
and 72 hr of induction.
Other genes among the most strongly up-regulated (>2-
fold) in the producer strain were also related to cellular
responses to different stresses, including oxidative (SUB1,
GRE2, HOR2, SOD2, ATX1, HSP12, GRX5, PRX1, TSA2,
GPX1, NCE103, CCP1, TRX2, AAD6) and osmotic (GRE2,
PAI3, HOT1, HOR2, HOR7, SIP18, HSP12, RHR2), as well
as other general stress responses (DDR2, SML1, XBP1,
MSN2, HAC1, CRZ1, DAK1, YGP1, SVS1, TIR2, HSP12,
ICT1, SPG4, HOR7). Some of the genes, such as HSP12
(heat shock protein), appeared in multiple categories of
stresses, and it was difficult to link the induction of some
genes to a specific class of stress response. It needs to be
further evaluated if those responses are the direct conse-
quence of artemisinic acid and its synthesis or secondary
effects. In summary, these data suggest that artemisinic
acid production triggers a plethora of stress-related
Heat-map representation of some up-regulated yeast genes  identified by microarray analysis Figure 5
Heat-map representation of some up-regulated yeast 
genes identified by microarray analysis. Cluster 6 of k-
mean clustering (k = 11) result showing some of the most 
strongly up-regulated genes observed in this study. Green 
color indicates the relative induction level (log2 ratio scale). 
S. cerevisiae open reading frame (ORF) and gene names are 
indicated. Red, blue, and black dots indicate genes for ATP-
binding-cassette (ABC) superfamily, major facilitator super-
family (MFS), and oxidative stresses, respectively.BMC Biotechnology 2008, 8:83 http://www.biomedcentral.com/1472-6750/8/83
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responses in yeast with the major classes of induced genes
being the MFS and ABC-transporters.
Discussion
The necessity for biological processes utilizing renewable
resources becomes critical in part due to global warming
and depletion of petroleum. Most biological engineering
efforts have been focused on developing microbial sys-
tems that can be genetically altered to produce high-value
chemicals and petroleum substitutes. Although our
understanding of tuning microbes into efficient work-
horses for chemical production is still limited, technolog-
ical developments in synthetic biology promise to make
biological engineering more predictable, faster, and less
expensive [20]. All major classes of secondary metabolites
including phenylpropanoids, terpenoids, and polyketides
have been produced in microbes [7,8,13,21-25]. Yet most
of the natural products are still supplied primarily
through fungal fermentation and plant cultivation accom-
panied by subtle chemical modifications. In this respect,
the yeast engineered to produce artemisinic acid is not
only a step towards a potential economically viable
method for producing artemisinin at a commercial scale
but also a research model to study the microbial manufac-
ture of specialty and commodity chemicals.
In this study, we demonstrated that the production titer of
artemisinic acid can be increased by altering the plasmid
selection marker and culture medium. Without any opti-
mization, the artemisinic acid yields from both shake-
flask and bio-reactor cultivation of the engineered yeast
were 10-fold higher than those yields reported previously
[7]. Further optimization of gene expression and cultiva-
tion conditions in order to take advantage of the full met-
abolic capacity of these microbes should improve
artemisinic acid yields even more.
Although all of the amorphadiene produced was not com-
pletely oxidized to artemisinic acid, the conversion rate is
estimated to be at least 32% by simply comparing the
yields of amorphadiene and artemisinic acid (Figure 1B
and Figure 2B). However, this value may be underesti-
mated because the stability of pESC-Leu2d::T is two-fold
lower than that of pESC-Leu2d::ADS. Considering the
lower plasmid stability in artemisinic acid-producing
yeast strain, the conversion rate from amorphadiene to
artemisinic acid could be as high as 64%. We attempted to
measure the amorphadiene that was not oxidized in the
artemisinic acid-producing yeast by overlaying dodecane
in the culture; however, dodecane sequesters amorphadi-
ene efficiently and hence the total artemisinic acid pro-
duction was severely impaired by dodecane (data not
shown). Although almost immiscible, terpenes still have
a low, but measurable water solubility. For example, a
range of 5–30 mg per liter solubility in water was reported
for monoterpenes such as limonene, myrcene, and pinene
[26,27]. Thus, an excess of unoxidized amorphadiene is
likely to remain in the medium and diffuse through the
yeast membrane before being oxidized by AMO/CPR or
vaporized into the atmosphere. The sequestration of
amorphadiene by dodecane in cultures of artemisinic
acid-producing yeast suggests that AMO/CPR inside the
cell could not instantly oxidize endogenously produced
amorphadiene. It is difficult to accurately measure the "in-
cell conversion rate", but apparently the AMO/CPR-oxida-
tion capability needs to be improved to fully convert the
amorphadiene to artemisinic acid. Improvement of the
kinetic properties of P450s is likely to be challenging,
though such improvements have been demonstrated in a
microbial system [28]. Nonetheless, genes/enzymes in
plant secondary metabolism are evolutionarily recent,
and hence there may be room for further improvement of
their catalytic efficiencies by in vitro evolution or site-
directed mutagenesis.
It was unexpected that the plasmid stability of the yeast
strain expressing ADS in pESC-Leu2d reached 84% in non-
selective rich medium, which was the highest of all condi-
tions tested (Figure 1D). The plasmid stability in non-
selective medium was even higher than that of yeast strain
harboring the same plasmid in the selective medium. FPP
and other mevalonate pathway intermediates have been
reported to be cytotoxic in E. coli [21,29]. It is likely that
yeast is also under similar stresses when FPP and other
precursors accumulate inside the cells. In the yeast strain
expressing  ADS  on  pESC-Leu2d  in rich medium, the
expression level of ADS per cell could be elevated by plac-
ing it on a Leu2d-based high-copy plasmid and by supply-
ing a high-level of nutrients in rich medium. Hence,
potentially cytotoxic FPP could be rapidly converted to
amorphadiene, which is then transported or diffuses
across the plasma membrane and cell wall and evaporates
from the culture medium. The reduced intracellular con-
centration of FPP in cells harboring a high-copy ADS and
grown in rich medium might stabilize the plasmid har-
boring ADS. However, it should be noted that converting
too much FPP to amorphadiene could also be toxic to
cells as it would deplete precursors needed for ergosterol
production.
The mechanism of olefin secretion from plant cells
remains unknown, but hydrophobic olefins such as amor-
phadiene might be diffusible through the cell membrane
without involving transporters. During cultivation (and
production) at 30°C, amorphadiene is likely to diffuse
through the membrane, and the volatile amorphadiene is
readily vaporized. On the other hand, artemisinic acid
produced endogenously should be ionized under neutral
cytosolic conditions. Since ionized artemisinic acid
requires transporters to cross the yeast plasma membrane,BMC Biotechnology 2008, 8:83 http://www.biomedcentral.com/1472-6750/8/83
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engineered yeast might utilize its own non-specific trans-
porters to secrete artemisinic acid into the medium. As
artemisinic acid is likely to be produced faster than it can
be transported from the cell, the engineered yeast harbor-
ing the plasmid carrying AMO is at a selective disadvan-
tage relative to the same yeast with no plasmid, which
results in the low plasmid stabilities observed in non-
selective medium (Figure 2D). This suggests that artem-
isinic acid might have a certain level of cytotoxicity in
yeast.
The cellular stresses evoked by artemisinic acid were
reflected by the massive transcriptional induction of the
genes coding for ABC transporters as determined by RT-
PCR and q-PCR. The unbiased microarray analysis further
confirmed that the key ABC transporter genes (SNQ2,
YOR1, PDR15, and PDR5) were among the genes highly
up-regulated in the artemisinic acid-producing yeast.
Nonetheless, yeast appears to tolerate the high-level of
artemisinic acid by operating its efficient efflux pumps,
such as the ABC transporters. It is difficult at this stage to
identify the specific transporters or a group of transporters
responsible for the secretion of artemisinic acid from
yeast. In the future, it would be feasible to identify respon-
sible transporters by deleting transporter genes in the
engineered yeast or using deletion yeast strains to evaluate
their sensitivity to artemisinic acid as was previously dem-
onstrated in the artesunate (anti-malarial drug)-sensitivity
test in mutant yeasts [30]. The nature and kinetic compe-
tency of yeast efflux pumps for artemisinic acid are
unknown. Thus, the identification and proper expression
of authentic plant artemisinic acid transporters from the
plant Artemisia annua might enhance the efflux of artem-
isinic acid from engineered yeast. It would be interesting
to reconstitute plant transporters in engineered yeast to
see if plants have evolved an efficient transporter for a spe-
cific class of natural product such as sesquiterpenoids.
The global microarray analysis of transcriptomes of the
yeast producing artemisinic acid relative to the yeast pro-
ducing amorphadiene was used to identify the stress
responses associated with artemisinic acid production.
The microarray analysis confirmed that expression of
genes encoding ABC-transporters were up-regulated in
artemisinic acid-producing yeast. Additionally, microar-
ray data indicated multiple genes involved in oxidative
and osmotic stresses and other general stress-responses
were significantly up-regulated. Despite the difficulties in
distinguishing whether these responses were the direct
effects of artemisinic acid-related toxicity or indirect
effects from the initial stress responses, the T-profiler and
YEASTRACT analyses revealed that at least three cis-ele-
ments in multiple genes were clearly responsive to artem-
isinic acid and/or its biosynthesis. As predicted, the Pdr3p
and related transcription factors involved in multi-drug
resistant signaling pathways were identified, and Msn2p/
Msn4p- and Reb1p-binding motifs were also identified.
The reason for the involvement of the Reb1p (RNA
polymerase I enhancer binding protein) in the artemisinic
acid stress is not clear, but Msn2p/Msn4p might be related
to oxidative stress associated with artemisinic acid synthe-
sis as these zinc-finger transcription factors are known to
regulate superoxide dismutase and thiol peroxidase [31-
33]. In the P450 catalytic cycle, reactive oxygen species
(ROS) are formed when activation of molecular oxygen
and substrate oxygenation are uncoupled [34]. Cyto-
chrome P450 is a heme-thiolate enzyme in which the dis-
tal axial ligand of the heme-moiety is occupied by
conserved cysteine residue [35]. The strong electron dona-
tion by anionic thiolate to the heme moiety facilitates the
heterolysis of dioxygen occupying the position trans to the
thiolate [36,37]. When cysteine was altered to glycine in
the C439G AMO mutant, the heterolytic cleavage of diox-
ygen cannot occur, and hence ROS species are not gener-
ated.
Our microarray data are in general consistent with other
yeast mutant and microarray data describing the weak
acid stress-responses in yeast. The screening of gene-dele-
tion yeasts identified PDR5 and TPO1 as major resistant
determinants against the anti-malarial drug artesunate
(weak acid) which is remarkably consistent with our data
(PDR5 and TPO1 showed 9- and 4- fold induction at the
24 h time point; Figure 5)[30]. A comparison of yeast
genes induced by treatment with 2,4-dichlorophenoxy-
acetic acid (2,4-D) and those by artemisinic acid produced
by our engineered yeast revealed that multi-drug resist-
ance transporters belonging to ABC and MSF transporters
families (e.g. PDR5, PDR15, YOR1 and TPO1) were com-
mon genes strongly activated under both conditions [38].
Considering all data together, it is apparent that the engi-
neered yeast is under the cellular stress exerted by a weak
acid (i.e., artemisinic acid).
Finally, microarray data suggests that artemisinic acid
itself may evoke osmotic stress resulting from lipophilic
weak acid stress in the engineered yeast. Undissociated
artemisinic acid could passively diffuse into the yeast
cytosol where it dissociates into a proton and an artem-
isinic acid anion, which can be actively exported by the
cells, resulting in an accumulation of protons in the yeast
cytosol and its acidification. Alternatively, artemisinic
acid could directly cause a destabilization (e.g. increased
porosity) of the yeast cell wall, leading to decreased
plasma membrane stability. The glycosylphosphatidyli-
nositol (GPI)-anchored cell wall proteins, such as SPI1
and YGP1, are believed to strengthen cell walls to protect
yeast against stress caused by lipophilic weak acids, such
as the food preservative benzoic acid [39,40]. Induction of
these genes during artemisinic acid production (approxi-BMC Biotechnology 2008, 8:83 http://www.biomedcentral.com/1472-6750/8/83
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mately 1.7-fold and 4 fold, respectively) together with sev-
eral other genes inducible by osmotic stress indicates that
yeast tries to compensate for the membrane destabiliza-
tion effect of artemisinic acid.
The fact that yeast can tolerate multiple stresses and pro-
duce one gram of artemisinic acid per liter in a laboratory
scale bio-reactor suggests that yeast may be an ideal plat-
form to produce artemisinic acid or other related
lipophilic weak acids. Although the biological signifi-
cance of the pleiotropic drug response and oxidative and
osmotic stresses needs to be further investigated in this
context and the potential resistance determinants to
artemisinic acid production are still not clearly deter-
mined, this study provides a basis for endogenous artem-
isinic acid production-induced stresses and will be useful
in selecting future potential targets for metabolic engi-
neering.
Conclusion
Development of microbial platforms for the production
of pharmaceuticals and other industrial chemicals is an
important area of research. An engineered yeast strain that
synthesizes the drug precursor artemisinic acid was previ-
ously reported. We demonstrated here that the produc-
tion of artemisinic acid can be significantly improved by
modulating the selection marker of the expression plas-
mid and the composition of the culture medium. In addi-
tion, by combination of RT-PCR and microarray analysis,
we showed that the cellular responses to artemisinic acid
biosynthesis involve the induction of multiple pleiotropic
drug resistance genes [ATP-binding cassette (ABC) and
major facilitator superfamily (MSF) transporters] as well
as genes known to respond to oxidative and osmotic
stresses. The studies presented here provide the basis for
future strain optimization to improve artemisinic acid
production.
Methods
Plasmid construction
The Leu2d allele codes for an identical Leu2 protein
sequence, but a significant portion of its promoter was
deleted, leaving only a 29-bp promoter region. In order to
generate pRS425-Leu2d::ADS plasmid, the 5'-end of Leu2-
coding sequence from pRS425-Leu2::ADS was amplified
by PCR using a pair of primers: forward primer, 5'-
ACGGAGGCTTCATCGGAGATGATATCACCAAACATGTT
G-3', and a reverse primer, 5'-ATGTCT GCCCCTAAGAA-
GATCGTCGTTTTGCCAGGTGACCACGTTGG-3'. This PC
R-product was used as a template for the second PCR
using a pair of primers: a forward primer, 5'-ATAAC
GGAGGCTTCATCGGAGATGATATCACCAAACATGTT-
GCTGGTGATTATAATACC-3' and a reverse primer, 5'-CG
GGGCGCCTT TTTTTATATATATTTCAAGGATATACCATT-
GTAATGTCTGCCCCTAAGAAGATCG-3'. The deleted pro-
moter was introduced using the reverse primer. The PCR-
product was digested using EcoRV and NarI and cloned
into the EcoRV- and NarI-digested pRS425-Leu2::ADS.
In order to generate pESC-Leu2d vector, the pESC-Leu
plasmid was digested using EcoRV  and DraIII, and the
EcoRV- and DraIII-digested fragment from pRS425-
Leu2d::ADS was ligated into the pESC-Leu plasmid. The
ADS  expression cassette in pRS425-Leu2d::ADS  was
amplified by using primers 5'-GTCAATCACTACGTGTAG-
TACGGATTAGAAGCCGCCGAGC-3' and 5'-GTCAAT-
GCCGGCCAAATTAAAGCCTTCGAGCGTCCCA-3'. The
PCR-product was digested using DraIII  and  NaeI  and
ligated into the corresponding sites in pESC-Leu2d or
pESC-Leu. The coding sequence for AMO  from pESC-
URA::AMO/CPR  was digested using PacI  and  NotI  and
ligated into the PacI and NotI of pESC-Leu2d::ADS and
pESC-Leu::ADS. The coding sequence for CPR from pESC-
URA::AMO/CPR  was digested by NotI  and  NheI  and
ligated into the NotI and NheI sites of pESC-Leu2d::ADS/
AMO  and pESC-Leu::ADS/AMO, resulting in the plas-
mids, pESC-Leu2d::ADS/AMO/CPR and pESC-Leu::ADS/
AMO/CPR, respectively.
Yeast strains, cultivation and plasmid stability assay
Strains and their genotypes are given in Table 1. Strains
used are derivatives of BY4742 (MATαα his3Δ1 leu2Δ0
lys2Δ0 ura3Δ0) [41]. The chromosomal modifications
made to create strain EPY224 (BY4742 PGAL1-tHMGR
PGAL1-upc2-1 erg9::PMET3-ERG9 PGAL1-tHMGR PGAL1-ERG20
plus pRS425-Leu::ADS  and pESC-Ura::AMO/CPR) have
been previously described [7]. Strains (EPY300) used in
this study have the same genetic background as EPY224 or
have repaired URA3 and LYS2 (EPY331). Repair of ura3Δ0
and lys2Δ0 in EPY300 was accomplished by transforma-
tion with a URA3 PCR amplicon (PCR primers, 5'-CTAC-
CAGAATGATAACAAGTTTGGAC-3' and 5'-GTGGAACAG
TGGTAATTCCTACGA-3'), selecting for uracil autotrophy,
then transforming the resulting uracil autotroph with a
LYS2 PCR amplicon (PCR primers, 5'-GGTACCTTTTT-
GAACTTCGTCTC-3' and 5'-CATCATGCTGCGAA-
GAACTAAAG-3') and selecting for lysine autotrophy. All
OD600 (optical density at 600) measurements were taken
using a Beckman DU-640 spectrophotometer. Culture
tubes containing 5 mL of CSM medium with 2% glucose
omitting Leu, His, and Met were inoculated with the strain
of interest. These inocula were grown at 30°C to OD600
between 1 and 2. Unbaffled culture flasks (250 mL) con-
taining 50 mL CSM medium omitting Leu and His or YPG
medium (0.2% glucose and 1.8% galactose) supple-
mented with 1 mM Met were inoculated to an OD600 of
0.03–0.05 with the initial seed cultures for induction. For
plasmid stability determination, dilutions of the cultures
were plated on CSM or CSM without Leu (2% glucose)
and grown for 3–4 days at 30°C before counting colonies.BMC Biotechnology 2008, 8:83 http://www.biomedcentral.com/1472-6750/8/83
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Terpenoid detection by gas chromatography-mass 
spectrometry
Gas chromatography (GC) and GC-mass spectrometry
were used to identify and quantify amorphadiene and
artemisinic acid as described previously [7].
Semi-quantitative RT-PCR and real-time quantitative RT-
PCR
Cells induced in YPG were harvested by quick centrifuga-
tion and immediately frozen in liquid nitrogen. Cells
were disrupted with glass beads in a bead beater, and total
RNA was extracted using the RNEasy Mini kit (QIAgen)
following the manufacturer's recommendations. RNA was
quantified by spectrophotometry, and its integrity verified
with a 2100 Bioanalyzer (Agilent). The RNA (450 ng) was
treated with the Turbo-DNA free kit (Ambion), and 350
ng of the treated RNA was reverse-transcribed with Super-
Script III (Invitrogen) using an oligo(dT) primer follow-
ing manufacturer's recommendations. The cDNA
synthesis reactions were treated with RNAse H, diluted
five fold, and 2 μl of the diluted cDNA served as template
for PCR. The PCR primers used were the following: ACT1
(5'-GCAAACCGCTGCTCAATCTTCT-3' and 5'-CAAAGCG
GTGATTTCCTTTTGC-3');  PDR1  (5'-ACTTACCGCAGCC
CTTTGTGAG-3' and 5'-TGTCGCATGTGAAGTCCACGTA-
3'); PDR3 (5'-TTCTCCTTGCCCCAT CAAGAAA-3' and 5'-
CTCCCAACGAGACAATCCCATC-3'); PDR5 (5'-TTTTCTA
GTGCCGCCTGGGTTA-3' and 5'-CACCTGGGTTTAGGCA
ACCATC-3'); PDR12 (5'-TGTCCCGAGCTTGATTTCCATT-
3' and 5'-CCTCTTGTGGCGTTATCCCAAG-3'); PDR15 (5'-
TGTTGGTGTTGCAGGT GAAGGT-3' and 5'-AGGGTTT-
GCATCAGGTGGACAT-3');  SNQ2  (5'-AACCGCGTT-
GACTGATCCAAAT-3' and 5'-AAAAGCACCGGAAGTGGA
TGAA-3'); and YOR1 (5'-GGAGGCTCCAGAAGATGATCC
A-3' and 5'-CTAAATCTTCCGGGCCGTCTCT-3'). For
semi-quantitative PCR, reactions were conducted for the
indicated number of cycles, and products were visualized
on agarose gels using standard techniques. For quantita-
tive PCR, 2X master mixes (DyNAmo HS SYBR Green
qPCR kit, Finnzymes or iQ SYBR Green Supermix, Bio-
Rad) were used according to manufacturer's recommen-
dations on a Bio-Rad iCycler instrument. Three independ-
ent transformants of each strain were assayed in triplicate
(n = 9), and the coefficient of variation of CT for all repli-
cate measurements was < 3%. Relative gene expression
was calculated using the Pfaffl method [42] with ACT1 as
the reference transcript.
Microarray analysis
Five independent transformants of each strain were
induced in YPG and harvested by centrifugation after 24,
48 and 72 h of induction and cell pellets were immedi-
ately frozen in liquid nitrogen. Total RNA was prepared by
hot acid phenol extraction [43] and further purified on an
RNEasy mini column (QIAgen). The RNA integrity was
verified using a 2100 Bioanalyzer (Agilent). Equal
amounts of total RNA from five clones of each strain were
pooled. Twenty (20) μg of each sample was used for
reverse transcription and fluorescent labeling with Super-
Script Plus Indirect cDNA Labeling System (Invitrogen)
following the manufacturer's recommendations, except
for the chemical hydrolysis of RNA and cDNA purifica-
tions, which were carried according to standard protocols
http://cmgm.stanford.edu/pbrown/protocols/amino-
allyl.htm. Labeled cDNA targets were hybridized to cDNA
microarray slides double-spotted with the 6,240 predicted
ORFs of S. cerevisiae (University Health Network Microar-
ray Facility, Toronto, Canada) and washed using standard
methods on a hybridization station (TECAN). Images
were acquired with a GenePix Professional 4200A scanner
(Axon Instruments), and feature fluorescence intensities
were extracted with the GenePix Pro 6.1 software. Four or
five replicates slides for each time point were hybridized.
Artifactual or aberrant spots were excluded, as well as
spots with low signal in both channels and spots for
which more than 50% of the values were missing. Lowess
normalization was performed using BRB-ArrayTools ver-
sion 3.5.0 developed by Dr. Richard Simon and Amy Peng
Lam http://linus.nci.nih.gov/BRB-ArrayTools.html. Sig-
nificant differentially expressed genes were extracted using
the SAM software [44], with false discovery rate set at ≤
0.2%. Clustering and gene ontology analyses were per-
formed on the significantly differentially expressed genes
using Genesis 1.7.1 [45].
Bioreactor
The fermentation was carried using a Sartorius Biostat B+
bioreactor. The temperature was kept at 30°C and pH was
kept at 5.5 with addition of 4 M NaOH. The OD was mon-
itored using an Optek ASD19-N single channel NIR
absorption probe and the off-gas analysis was monitored
by a Thermo Onix VG Prima δB mass-spectrometer. The
yeast was firstly grown in batch fermentation with 27 g L-
1 initial glucose concentration, vitamins and trace metals
solution in an initial volume of 720 ml. When glucose
was depleted after approximately 21 h, a solution of 186
g L-1 of glucose, vitamins and minerals started to be added
in the bioreactor with feed-rate addition controlled by a
D.O stat algorithm [46]. After 40 h, the OD reached
approximately 60 and the broth volume in the bioreactor
was approximately 920 ml. At this point, production was
induced by another feed solution containing 377 g L-1 of
galactose, vitamins and trace metals which was added into
the bioreactor for 72 h at a feed rate also controlled the
D.O. stat.
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